Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region

被引:53
作者
Amanuel, Benhur [3 ]
Grieu, Fabienne [3 ]
Kular, Jasreen [1 ]
Millward, Michael [2 ]
Iacopetta, Barry [1 ]
机构
[1] Univ Western Australia, Sch Surg, Nedlands, WA 6009, Australia
[2] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA 6009, Australia
[3] Sir Charles Gairdner Hosp, Nedlands, WA 6009, Australia
关键词
BRAF; melanoma; p.Val600Glu; p.Val600Lys; PLX4032; vemurafenib; INHIBITOR PLX4032; V600E MUTATION; NRAS MUTATIONS; PROLIFERATION; CANCER; RAF;
D O I
10.1097/PAT.0b013e3283532565
中图分类号
R36 [病理学];
学科分类号
100103 [病原生物学];
摘要
Aim: Approximately 40-60% of melanomas from Caucasian populations carry activating mutations in the BRAF oncogene, with the most common being the p.Val600Glu (V600E) hotspot mutation in exon 15. The aim of the present study was to investigate the frequency of the less common p.Val600Lys (V600K) mutation in metastatic melanoma from a high incidence region. Method: Dideoxy sequencing and fluorescent single strand conformation analysis were used to screen for mutations in exon 15 of BRAF in 183 cases of metastatic melanoma. Results: The overall incidence of BRAF mutation (89/183, 49%) was very similar to other large studies of Caucasian populations. However, the frequency of the p.Val600Lys mutation was higher than in most other studies and comprised almost one-third of all BRAF mutations in our cohort (27/89, 30%). Conclusion: BRAF p.Val600Lys mutations were present at a relatively high frequency in this cohort of metastatic melanoma patients (27/183, 15%). Assays used to screen for BRAF mutations in the clinic should be robust enough to detect the p.Val600Lys mutation, as this may have therapeutic implications.
引用
收藏
页码:357 / 359
页数:3
相关论文
共 14 条
[1]
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].
Chapman, Paul B. ;
Hauschild, Axel ;
Robert, Caroline ;
Haanen, John B. ;
Ascierto, Paolo ;
Larkin, James ;
Dummer, Reinhard ;
Garbe, Claus ;
Testori, Alessandro ;
Maio, Michele ;
Hogg, David ;
Lorigan, Paul ;
Lebbe, Celeste ;
Jouary, Thomas ;
Schadendorf, Dirk ;
Ribas, Antoni ;
O'Day, Steven J. ;
Sosman, Jeffrey A. ;
Kirkwood, John M. ;
Eggermont, Alexander M. M. ;
Dreno, Brigitte ;
Nolop, Keith ;
Li, Jiang ;
Nelson, Betty ;
Hou, Jeannie ;
Lee, Richard J. ;
Flaherty, Keith T. ;
McArthur, Grant A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516
[2]
Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[3]
BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes [J].
El-Osta, Hazem ;
Falchook, Gerald ;
Tsimberidou, Apostolia ;
Hong, David ;
Naing, Aung ;
Kim, Kevin ;
Wen, Sijin ;
Janku, Filip ;
Kurzrock, Razelle .
PLOS ONE, 2011, 6 (10)
[4]
Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma [J].
Ellerhorst, Julie A. ;
Greene, Victoria R. ;
Ekmekcioglu, Suhendan ;
Warneke, Carla L. ;
Johnson, Marcella M. ;
Cooke, Carolyn P. ;
Wang, Li-E ;
Prieto, Victor G. ;
Gershenwald, Jeffrey E. ;
Wei, Qingyi ;
Grimm, Elizabeth A. .
CLINICAL CANCER RESEARCH, 2011, 17 (02) :229-235
[5]
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma [J].
Flaherty, Keith T. ;
Puzanov, Igor ;
Kim, Kevin B. ;
Ribas, Antoni ;
McArthur, Grant A. ;
Sosman, Jeffrey A. ;
O'Dwyer, Peter J. ;
Lee, Richard J. ;
Grippo, Joseph F. ;
Nolop, Keith ;
Chapman, Paul B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (09) :809-819
[6]
PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells [J].
Halaban, Ruth ;
Zhang, Wengeng ;
Bacchiocchi, Antonella ;
Cheng, Elaine ;
Parisi, Fabio ;
Ariyan, Stephan ;
Krauthammer, Michael ;
McCusker, James P. ;
Kluger, Yuval ;
Sznol, Mario .
PIGMENT CELL & MELANOMA RESEARCH, 2010, 23 (02) :190-200
[7]
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner [J].
Joseph, Eric W. ;
Pratilas, Christine A. ;
Poulikakos, Poulikos I. ;
Tadi, Madhavi ;
Wang, Weiqing ;
Taylor, Barry S. ;
Halilovic, Ensar ;
Persaud, Yogindra ;
Xing, Feng ;
Viale, Agnes ;
Tsai, James ;
Chapman, Paul B. ;
Bollag, Gideon ;
Solit, David B. ;
Rosen, Neal .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (33) :14903-14908
[8]
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis [J].
Lee, J. -H. ;
Choi, J. -W. ;
Kim, Y. -S. .
BRITISH JOURNAL OF DERMATOLOGY, 2011, 164 (04) :776-784
[9]
BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status [J].
Li, Wei Qi ;
Kawakami, Kazuyuki ;
Ruszkiewicz, Andrew ;
Bennett, Graeme ;
Moore, James ;
Iacopetta, Barry .
MOLECULAR CANCER, 2006, 5 (1)
[10]
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma [J].
Long, Georgina V. ;
Menzies, Alexander M. ;
Nagrial, Adnan M. ;
Haydu, Lauren E. ;
Hamilton, Anne L. ;
Mann, Graham J. ;
Hughes, T. Michael ;
Thompson, John F. ;
Scolyer, Richard A. ;
Kefford, Richard F. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (10) :1239-1246